Pulmonary Embolism - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Pulmonary Embolism - Pipeline Review, H1 2019’, provides an overview of the Pulmonary Embolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism

- The report reviews pipeline therapeutics for Pulmonary Embolism by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Pulmonary Embolism therapeutics and enlists all their major and minor projects

- The report assesses Pulmonary Embolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Pulmonary Embolism

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pulmonary Embolism

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pulmonary Embolism pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Accu-Break Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

F. Hoffmann-La Roche Ltd

Tasly Pharmaceutical Group Co Ltd

Verseon Corp

Accu-Break Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

F. Hoffmann-La Roche Ltd

Tasly Pharmaceutical Group Co Ltd

Verseon Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pulmonary Embolism – Overview

Pulmonary Embolism – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pulmonary Embolism – Overview

Pulmonary Embolism – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pulmonary Embolism – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pulmonary Embolism – Companies Involved in Therapeutics Development

Accu-Break Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

F. Hoffmann-La Roche Ltd

Tasly Pharmaceutical Group Co Ltd

Verseon Corp

Pulmonary Embolism – Drug Profiles

DS-1040 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heparin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

urokinase – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-1902 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-2851 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

warfarin potassium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pulmonary Embolism – Dormant Projects

Pulmonary Embolism – Discontinued Products

Pulmonary Embolism – Product Development Milestones

Featured News & Press Releases

Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pulmonary Embolism, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development ...

List of Tables

Number of Products under Development for Pulmonary Embolism, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pulmonary Embolism – Pipeline by Accu-Break Pharmaceuticals Inc, H1 2019

Pulmonary Embolism – Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Pulmonary Embolism – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019

Pulmonary Embolism – Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Pulmonary Embolism – Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2019

Pulmonary Embolism – Pipeline by Verseon Corp, H1 2019

Pulmonary Embolism – Dormant Projects, H1 2019

Pulmonary Embolism – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Pulmonary Embolism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Pulmonary Embolism, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports